Home
Home » companies

Protalix BioTherapeutics

3 Ways Big Pharma Is Seizing This Rare Opportunity

3 Ways Big Pharma Is Seizing This Rare Opportunity
Motley Fool

This Week in Biotech

This Week in Biotech
Motley Fool

Protalix extends collaboration on Gaucher disease drug; Pfizer will manage new Elelyso trials

Protalix extends collaboration on Gaucher disease drug; Pfizer will manage new Elelyso trials
Yahoo/AP

Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline

Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline
Seeking Alpha

A Home Run Drug in the Holy Land

A Home Run Drug in the Holy Land
Motley Fool

Why Protalix BioTherapeutics Plunged

Why Protalix BioTherapeutics Plunged
Motley Fool

Protalix Receives a $25 Million Milestone Payment for U.S. Approval of ELELYSO(TM)

Protalix Receives a $25 Million Milestone Payment for U.S. Approval of ELELYSO(TM)
Yahoo

Protalix Biotherapeutics attractive as long term holding – and takeover target

Protalix Biotherapeutics attractive as long term holding – and takeover target
NASDAQ

Pfizer Should Rise On New Gaucher Drug, Due Out In 2013

Pfizer Should Rise On New Gaucher Drug, Due Out In 2013
Seeking Alpha

U.S. FDA approves Pfizer/Protalix drug for Gaucher

U.S. FDA approves Pfizer/Protalix drug for Gaucher
Reuters